Endocrinology

Nearly 40% of perimenopausal women report misdiagnosis as clinicians treat for anxiety and depression without addressing underlying hormonal imbalance.

Recognize Cushing syndrome in primary care: key clinical clusters, first-line screening tests (DST, salivary cortisol, UFC), and when to refer to endocrinology.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.

Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Your daily dose of the clinical news you may have missed.

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.

Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.

The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Your daily dose of the clinical news you may have missed.

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

New research reveals GLP-1 receptor agonists may alter PET-CT scan interpretations, highlighting the need for updated guidelines in oncological imaging.

Time in range, glucose variability, and postprandial spikes: Anderson highlights how CGM insights translate quickly into targeted treatment decisions.

The Frist Clinic clinician said that technical difficulty is not impeding CGM uptake in primary care. "The real limitation is they just haven't done it before."

John E Anderson, MD, discusses why primary care lags in CGM adoption despite proven benefits, stressing that it's largely a lack of familiarity and that's easily overcome.

Your daily dose of the clinical news you may have missed.